The present invention relates to the use of cromoglicic acid and/or nedocromil salts in pharmaceutically effective amounts in a pharmaceutical composition containing salmeterol or a pharmaceutically acceptable salt thereof as a 32-agonisti combined with fluticasone or a pharmaceutically acceptable salt thereof as a corticosteroid for the treatment of the respiratory diseases.